Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a clinical study titled ‘A ...

AbbVie is conducting a study titled ‘SUNRISE-UC’ to evaluate the effectiveness and safety of Risankizumab in patients with moderate to severe ulcerative colitis. This real-world study aims to assess ...

Risankizumab is an interleukin (IL)-23 p19 inhibitor that was approved for the treatment of adults with moderately to severely active Crohn's disease in June 2022, while ustekinumab is an IL-12/23 ...

The trial has an estimated study completion date of February 2028. Risankizumab was FDA approved in 2022 for adults with moderate-to-severe CD, as was ustekinumab in 2016.

In the risankizumab arm, 84.7% of patients achieved PASI 75 at week 16 vs 18.8% of patients in the apremilast arm (secondary endpoint; P <.001).

At week 16, 55.9% of the risankizumab group and 5.1% of the apremilast group achieved PASI 90. 75.4% of risankizumab-treated patients vs. 18.4% of apremilast-treated patients achieved sPGA 0/1 by ...

Risankizumab, an interleukin-23 (IL-23) inhibitor, is currently marketed under the trade name Skyrizi and is approved for the treatment of active psoriatic arthritis, moderately to severely active ...

The FDA approved risankizumab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the p19 subunit of interleukin (IL)-23, in March 2019 for the treatment PsA in adults.

Risankizumab appeared to worsen severe asthma symptoms compared with placebo, according to results of a randomized phase 2a study published in The New England Journal of Medicine. Risankizumab ...

3.3 Risankizumab is a novel treatment with a different mechanism of action to existing treatments. The company proposed it can be used either after conventional treatment (conventional care failure ...

Risankizumab is approved in the United States for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It is a humanized ...

In the risankizumab group, median time to first asthma worsening was 40 days, significantly worse than the 86 days reported for the placebo group (hazard ratio, 1.46; 95% CI, 1.05 – 2.04; P = .03).